NCT03188146Completed
Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
Performance of Biochemical Response Criteria and Risk Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
Source: ClinicalTrials.gov · Last updated 24 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Several risk assessment scoring systems have been proposed to assess the therapeutic response and predict long term prognosis in ursodeoxycholic acid (UDCA)-treated primary biliary cholangitis (PBC) patients, in order to risk stratify PBC patients and guide their management. However there scoring systems have not been fully validated in Chinese population. This study is going to compare the prognostic ability of these criteria, validate the overseas scoring systems, develop and validate a new scoring system in a cohort of Chinese PBC patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 57 (actual)
- First submitted
- 8 Jun 2017
- Start date
- 1 May 2017
- Primary completion date
- 15 Feb 2025
- Lead sponsor
- Humanity and Health Research Centre
- Diseases
- Primary biliary cholangitis
- NCT number
- NCT03188146
What you commit to
- Study type: Observational
- Participants enrolled: 57
- From 1 May 2017 to the primary completion date, 15 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A positive serological test for hepatitis B or C virus,
- Alcoholic liver disease,
- Wilson's disease,
Lab values
- Presence of complications of cirrhosis (Total bilirubin \>100 lmol/L, ascites, variceal haemorrhage and hepatic encephalopathy) on admission.
Other
- Comorbidity of primary sclerosing cholangitis,
- Hemochromatosis,
- a1-antitrypsin deficiency
Who the study is looking for
- With liver biopsy proved PBC
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre of non-infectious liver diseases, Beijing 302 Hospital, Beijing, China. Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.